Back to discover
Drug

Relatlimab

In clinical development
ClassLymphocyte activation gene 3 protein inhibitorEmerging researchLate-stage development

Also known as Opdualag.

RxNorm2596773ChEMBLCHEMBL3990044UNIIAF75XOF6W3
1
Research papers
20
Active clinical trials
LAG3
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Molecular Analysis for Therapy Choice (MATCH)

Clinical trial2026-07-31Results expected Q4 2026 · ClinicalTrials.gov

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer

Clinical trial2026-07-07Results expected Q3 2030 · ClinicalTrials.gov

Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies

Clinical trial2026-07-02Results expected Q3 2029 · ClinicalTrials.gov

A Phase 2 Trial in Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment With Platinum-Gemcitabine-Nivolumab for Patients With Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)

Clinical trial2026-07-01Results expected Q2 2029 · ClinicalTrials.gov

A Phase II Study of PD-1 Blockade With or Without LAG-3 Inhibition in Combination With Infliximab for the Treatment of Metastatic Melanoma and Prevention of Adverse Events

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%

Clinical trial2026-06-23Results expected Q3 2030 · ClinicalTrials.gov

A Phase II Neoadjuvant Study of the Safety and Tolerability of Anti-PD1 (Nivolumab) Administered Alone or in Combination With Anti-LAG3 (Relatlimab) or Anti-CTLA4 (Ipilimumab) in Resectable Head and Neck Cancer

Clinical trial2026-06-23Results expected Q4 2027 · ClinicalTrials.gov

A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Clinical trial2026-06-18Results posted · ClinicalTrials.gov

Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases

Clinical trial2026-05-15Results expected Q3 2028 · ClinicalTrials.gov

REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer

Clinical trial2026-05-06Results expected Q4 2026 · ClinicalTrials.gov

Neoadjuvant relatlimab and nivolumab in resectable melanoma.

Research2022-10-26Nature

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Relatlimab
Aliases & brands
Opdualag
RxNorm CUI
2596773
ChEMBL ID
CHEMBL3990044
UNII
AF75XOF6W3
Primary mechanism
Lymphocyte activation gene 3 protein inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Lymphocyte activation gene 3 protein
LAG3 · P18627
INHIBITORLymphocyte activation gene 3 protein inhibitor

Clinical trials

47 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
47
registered trials across all phases
LATEST COMPLETION 2026
20
Active studies
10
Recruiting
4
Late-stage (III+)
18
Completed
9
Discontinued
PHASE DISTRIBUTIONn = 47
Phase 17Phase 1 / 29Phase 227Phase 2 / 32Phase 31Phase 41

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Multi-center Trial Evaluating the ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab for Advanced Melanoma

RecruitingPH IVNYU Langone Healthn=902031

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%

RecruitingPH IIIKey trialBristol-Myers Squibbn=1,0002032

A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma

Active, not recruitingPH II/IIIBristol-Myers Squibbn=7142030

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer

RecruitingPH II/IIINational Cancer Institute (NCI)n=9922030

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

CompletedPH IIBristol-Myers Squibbn=4682026

A Phase 2 Study of Nivolumab + BMS-986016 (Relatlimab) in Patients With Metastatic Uveal Melanoma

CompletedPH IIJose Lutzky, MDn=272026

A Phase 2, Randomized, Open-label Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Hepatocellular Carcinoma Who Are Naive to IO Therapy But Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)

CompletedPH IIBristol-Myers Squibbn=2662025

A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma

CompletedPH I/IIBristol-Myers Squibbn=832025

A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

CompletedPH I/IIBristol-Myers Squibbn=2292025

A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

CompletedPH I/IIBristol-Myers Squibbn=1,4822025

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Neoadjuvant relatlimab and nivolumab in resectable melanoma.

Nature · 2022 · 240 cites
Recent papers

Neoadjuvant relatlimab and nivolumab in resectable melanoma.

Nature · 2022 · 240 cites
Major research themes3
Melanoma1Neoadjuvant Therapy1Nivolumab1
Journals, researchers & institutions
Top journals
  • Nature1
Leading researchers
  • Allison JP1
  • Amaria RN1
  • Ariyan C1
  • Bartlett EK1
  • Bello D1
  • Betof-Warner A1
  • Burton EM1
  • Busam K1
Leading institutions
free-text, unnormalised
  • Memorial Sloan Kettering Cancer Center1
  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College1
  • The University of California San Francisco1
  • The University of Texas MD Anderson Cancer Center1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials